Antibodies are the number one immune cells that fight against infection and diseases. However, beyond their natural usage, biochemistry has devised several ways in which these antibodies can be ...

- EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for the development and manufacturing of ...

Recombinant antibody technology has been leveraged to mitigate a range of common problems associated with hybridoma platforms, helping to facilitate the development of an entirely new class of ...

In September 1970, Janet Mertz joined the biochemistry department at Stanford University. She was one of only six new graduate students in the department and the first female one admitted in nine ...

THE STRUCTURE AND FUNCTION OF RECOMBINANT HUMANIZED TYPE III COLLAGEN AS WELL AS ITS RELATED PRODUCT approved by CHINA NMPa for COSMETICS USE (ADAPTED FROM THE AUTHORS’ PUBLICATION IN Biochemical and ...

A phase II trial of an adenovirus/PSA vaccine for prostate cancer No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2009 ASCO Annual Meeting I. This ...

The clinical diagnostic industry is on the verge of a recombinant protein revolution. Recombinants have been available for decades and have served some sectors of diagnostics quite well, but they have ...

LYON, France--(BUSINESS WIRE)--BioNet Europe, the French subsidiary of BioNet, a vaccine manufacturer specializing in the development of genetically engineered vaccines, has announced the submission ...

Key market opportunities in the global competent cells market include rising demands in genetic engineering and synthetic biology sectors, driven by advancements in molecular cloning, drug discovery, ...